Skip to main content
SpringerLink
Log in

Multidisciplinary Overview of Local-Regional Therapies for Liver Malignancies

  • Chapter
Treating Tumors that Move with Respiration

  • 1070 Accesses

Abstract

This chapter reviews, from the surgeon’s perspective, the various local-regional treatments for hepatic malignancies and how the use of stereotactic radiosurgery fits into current general surgical practice. Understanding these modalities is important in surgical practice and enables a rational approach to both surgical and non-surgical therapies for hepatic malignancies. Some of these treatments are clearly in the surgical domain as these therapies may be best given via laparoscopic or open surgical approach. Additionally, these local-regional modalities are increasingly being used as neoadjuvant or adjuvant therapy, particularly in Hepatocellular Carcinoma (HCC). Surgeons are faced with the challenge of adopting these alternative techniques into their practice. Familiarity with these therapies allows the surgeon, with their unique expertise and skill, to participate actively in the nonsurgical management of these lesions. Several of the more prominent nonsurgical local-regional therapies are reviewed here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979–94. Lancet 1997;350:1142–1143.

    Article  PubMed  CAS  Google Scholar 

  2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.

    Article  PubMed  CAS  Google Scholar 

  3. Devita V. Cancer: Principles and Practice of Oncology. Sixth ed: Lippincott Williams and Wilkins; 2001.

    Google Scholar 

  4. Poon RT, Fan ST, Lo cm, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70.

    Article  PubMed  CAS  Google Scholar 

  5. Colella G, Bottelli R, De Carlis L, et al. Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int 1998;11Suppl 1:S193–196.

    Article  PubMed  Google Scholar 

  6. Fan ST, Lo cm, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322–330.

    Article  PubMed  CAS  Google Scholar 

  7. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790–799; discussion 799–800.

    Article  PubMed  CAS  Google Scholar 

  8. Mor E, Kaspa RT, Sheiner P, et al. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998;129:643–653.

    PubMed  CAS  Google Scholar 

  9. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311–322.

    Article  PubMed  CAS  Google Scholar 

  10. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988;15:1–31.

    Article  PubMed  CAS  Google Scholar 

  11. Mathurin P, Rixe O, Carbonell N, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111–126.

    Article  PubMed  CAS  Google Scholar 

  12. Poon RT, Fan ST, Tsang FH, et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg 2002;235:466–486.

    Article  PubMed  Google Scholar 

  13. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025–1033.

    Article  PubMed  CAS  Google Scholar 

  14. Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861–870.

    PubMed  CAS  Google Scholar 

  15. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001;19:164–170.

    PubMed  CAS  Google Scholar 

  16. Buscarini L, Rossi S. Technology for Radiofrequency Thermal Ablation of Liver Tumors. Semin Laparosc Surg 1997;4:96–101.

    PubMed  Google Scholar 

  17. Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7:593–600.

    PubMed  CAS  Google Scholar 

  18. Goletti O, Lencioni R, Armillotta N, et al. Laparoscopic radiofrequency thermal ablation of hepatocarcinoma: preliminary experience. Surg Laparosc Endosc Percutan Tech 2000;10:284–290.

    Article  PubMed  CAS  Google Scholar 

  19. Montorsi M, Santambrogio R, Bianchi P, et al. Radiofrequency interstitial thermal ablation of hepatocellular carcinoma in liver cirrhosis. Role of the laparoscopic approach. Surg Endosc 2001;15:141–145.

    Article  PubMed  CAS  Google Scholar 

  20. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655–661.

    PubMed  CAS  Google Scholar 

  21. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214:761–768.

    PubMed  CAS  Google Scholar 

  22. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201–1209.

    Article  PubMed  Google Scholar 

  23. Lencioni R, Della Pina C, Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging 2005;30:401–408.

    Article  PubMed  CAS  Google Scholar 

  24. Lin SM, Lin CJ, Lin cc, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714–1723.

    Article  PubMed  Google Scholar 

  25. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235–240.

    Article  PubMed  Google Scholar 

  26. Giorgio A, Tarantino L, de Stefano G, et al. Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181:479–484.

    PubMed  Google Scholar 

  27. Rhim H. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow: comparison with standard percutaneous radiofrequency ablation therapy. Cancer 2003;98:433–434; author reply 434–435.

    Article  PubMed  Google Scholar 

  28. Livraghi T, Meloni F. Treatment of hepatocellular carcinoma by percutaneous interventional methods. Hepatogastroenterology 2002;49:62–71.

    PubMed  Google Scholar 

  29. Meloni MF, Goldberg SN, Moser V, et al. Colonic perforation and abscess following radiofrequency ablation treatment of hepatoma. Eur J Ultrasound 2002;15:73–76.

    Article  PubMed  Google Scholar 

  30. Patterson EJ, Scudamore CH, Owen DA, et al. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg 1998;227:559–565.

    Article  PubMed  CAS  Google Scholar 

  31. Matsui O, Kadoya M, Yoshikawa J, et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994;33Suppl:S84–88.

    Article  PubMed  Google Scholar 

  32. Bhattacharya S, Novell JR, Winslet MC, et al. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994;81:1563–1571.

    Article  PubMed  CAS  Google Scholar 

  33. Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33Suppl:S149–152.

    Article  PubMed  Google Scholar 

  34. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991;68:2150–2154.

    Article  PubMed  CAS  Google Scholar 

  35. Hsieh MY, Chang WY, Wang LY, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. Cancer Chemother Pharmacol 1992;31Suppl:S82–85.

    Article  PubMed  Google Scholar 

  36. Yang CF, Ho YJ. Transcatheter arterial chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992;31Suppl:S86–88.

    Article  PubMed  Google Scholar 

  37. Yamamoto K, Masuzawa M, Kato M, et al. Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Cancer Chemother Pharmacol 1992;31Suppl:S77–81.

    Article  PubMed  Google Scholar 

  38. Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992;163:387–394.

    Article  PubMed  CAS  Google Scholar 

  39. Ngan H, Lai CL, Fan ST, et al. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol 1993;47:315–320.

    Article  PubMed  CAS  Google Scholar 

  40. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994;19:1115–1123.

    PubMed  CAS  Google Scholar 

  41. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129–134.

    Article  PubMed  CAS  Google Scholar 

  42. Okada S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 1998;27:1743–1744.

    Article  PubMed  CAS  Google Scholar 

  43. Poon RT, Ngan H, Lo cm, et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000;73:109–114.

    Article  PubMed  CAS  Google Scholar 

  44. Zhu LX, Wang GS, Fan ST. Spontaneous rupture of hepatocellular carcinoma. Br J Surg 1996;83:602–607.

    Article  PubMed  CAS  Google Scholar 

  45. Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 1999;172:59–64.

    PubMed  CAS  Google Scholar 

  46. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996;111:720–726.

    Article  PubMed  CAS  Google Scholar 

  47. Imaoka S, Sasaki Y, Shibata T, et al. A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 1989;23Suppl:S126–128.

    Article  PubMed  Google Scholar 

  48. Wu cc, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995;82:122–126.

    Article  PubMed  CAS  Google Scholar 

  49. Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996;87:206–211.

    PubMed  CAS  Google Scholar 

  50. Gerunda GE, Neri D, Merenda R, et al. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl 2000;6:619–626.

    Article  PubMed  CAS  Google Scholar 

  51. Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996;224:4–9.

    Article  PubMed  CAS  Google Scholar 

  52. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701; discussion 701–683.

    Article  PubMed  CAS  Google Scholar 

  53. Raoul JI, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 1992;69:346–352.

    Article  PubMed  CAS  Google Scholar 

  54. Kajiya Y, Kobayashi H, Nakajo M. Transarterial internal radiation therapy with I-131 Lipiodol for multifocal hepatocellular carcinoma: immediate and long-term results. Cardiovasc Intervent Radiol 1993;16:150–157.

    Article  PubMed  CAS  Google Scholar 

  55. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35:1313–1318.

    PubMed  CAS  Google Scholar 

  56. Maini CL, Scelsa MG, Fiumara C, et al. Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma. Clin Nucl Med 1996;21:221–226.

    Article  PubMed  CAS  Google Scholar 

  57. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156–1161.

    PubMed  CAS  Google Scholar 

  58. de Baere T, Taourel P, Tubiana JM, et al. Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. Radiology 1999;212:665–668.

    PubMed  Google Scholar 

  59. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797–801.

    Article  PubMed  CAS  Google Scholar 

  60. Garrean S, Joseph Espat N. Yttrium-90 internal radiation therapy for hepatic malignancy. Surg Oncol 2005;14:179–193.

    Article  PubMed  Google Scholar 

  61. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10:S107–110.

    Article  PubMed  Google Scholar 

  62. Furuse J, Satake M, Iwasaki M, et al. Percutaneous ethanol injection under interventional radiographic computed tomography-fluoroscopic guidance for the treatment of small hepatocellular carcinomas. Int J Clin Onco 1998;3:102–107.

    Article  Google Scholar 

  63. Oldhafer KJ, Chavan A, Fruhauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998;29:953–959.

    Article  PubMed  CAS  Google Scholar 

  64. Schwartz ME, Sung M, Mor E, et al. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 1995;180:596–603.

    PubMed  CAS  Google Scholar 

  65. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984;199:502–508.

    Article  PubMed  CAS  Google Scholar 

  66. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999;26:514–523.

    PubMed  CAS  Google Scholar 

  67. Adson MA, van Heerden JA, Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;119:647–651.

    PubMed  CAS  Google Scholar 

  68. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994;116:703–710; discussion 710–701.

    PubMed  CAS  Google Scholar 

  69. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986;100:278–284.

    PubMed  CAS  Google Scholar 

  70. Schlag P, Hohenberger P, Herfarth C. Resection of liver metastases in colorectal cancer-competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 1990;16:360–365.

    PubMed  CAS  Google Scholar 

  71. Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992;216:493–504; discussion 504–495.

    Article  PubMed  CAS  Google Scholar 

  72. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–318; discussion 318–321.

    Article  PubMed  CAS  Google Scholar 

  73. Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001;177:645–655.

    Article  PubMed  CAS  Google Scholar 

  74. Kavanagh BD, Schefter TE, Cardenes HR, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006;45:848–855.

    Article  PubMed  Google Scholar 

  75. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159–166.

    Article  PubMed  CAS  Google Scholar 

  76. Oshowo A, Gillams A, Harrison E, et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003;90:1240–1243.

    Article  PubMed  CAS  Google Scholar 

  77. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2006.

    Google Scholar 

  78. Wagman LD, Kemeny mm, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885–1893.

    PubMed  CAS  Google Scholar 

  79. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459–465.

    PubMed  CAS  Google Scholar 

  80. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685–693.

    Article  PubMed  CAS  Google Scholar 

  81. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112–1118.

    PubMed  CAS  Google Scholar 

  82. Kemeny N, Cohen A, Seiter K, et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993;11:330–335.

    PubMed  CAS  Google Scholar 

  83. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252–258.

    Google Scholar 

  84. Kemeny mm, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002;20:1499–1505.

    Article  PubMed  Google Scholar 

  85. Tellez C, Benson AB, 3rd, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998;82:1250–1259.

    Article  PubMed  CAS  Google Scholar 

  86. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711–1720.

    Article  PubMed  CAS  Google Scholar 

  87. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225–235.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abdominal Radiosurgery Services, Hepatobiliary-Transplant Surgeon, Baylor University Medical Center, 3500 Gaston Ave, Dallas, TX, 75246, USA

    Robert M. Goldstein MD (Director)

  2. Baylor Radiosurgery Center, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX, 75246, USA

    Brian D. Berger MD (Associate Medical Director) & John K. O’Connor MD

Authors
  1. Robert M. Goldstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian D. Berger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John K. O’Connor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Research, Education and Clinical Excellence, Baylor University Medical Center, 1201 Barnett Tower 3600 Gaston Avenue, Dallas, TX, 75246, USA

    Harold C. Urschel Jr. MD (Chair of Cardiovascular and Thoracic Surgical) (Chair of Cardiovascular and Thoracic Surgical)

  2. Arizona Oncology Services at St. Joseph’s Hospital & Medical Center Department of Radiation Oncology CyberKnife Center Barrow Neurological Institute, Gamma Knife Center, 350 West Thomas Road, Phoenix, Arizona, 85013, USA

    John J. Kresl MD, PhD

  3. The Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, PUH, C-800, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    James D. Luketich MD (Sampson Family Endowed Professor of Surgery Chief) (Sampson Family Endowed Professor of Surgery Chief)

  4. Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX, 75390, USA

    Lech Papiez PhD (Associate Professor) & Robert D. Timmerman MD (Professor and Vice-Chairman Effie Marie Cain Distinguished Chair in Cancer Therapy Research) (Associate Professor) &  (Professor and Vice-Chairman Effie Marie Cain Distinguished Chair in Cancer Therapy Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Goldstein, R.M., Berger, B.D., O’Connor, J.K. (2007). Multidisciplinary Overview of Local-Regional Therapies for Liver Malignancies. In: Urschel, H.C., Kresl, J.J., Luketich, J.D., Papiez, L., Timmerman, R.D., Schulz, R.A. (eds) Treating Tumors that Move with Respiration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69886-9_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69886-9_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69885-2

  • Online ISBN: 978-3-540-69886-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation